Characteristics of patients on Lecanemab treatment at West China Hospital of Sichuan University: perspectives from real‐world experience.

Abstract

Background: Alzheimer’s disease (AD) poses a significant public health challenge in China. Recent advancements in disease‐modifying therapies, particularly lecanemab, have brought new therapeutic opportunities. In China, nationwide implementation of lecanemab in clinical practice was launched in June 2024.

The paper